HIV Prevention Clinical Trials Database

A comprehensive source of information on biomedical HIV prevention clinical trials

View Trials Map

Our database allows users to view planned, ongoing, and completed clinical trials around the world, gaining an understanding of the many developments currently being made in the field of HIV prevention research.

Search or Filter

Reset filters

Results

showing 1-20 of 134

Trial Name

HPTN 091

Prevention Option
PrEP
Start Date
March 21, 2021
End Date
November 30, 2024
Population
Cisgender Men
Country
Brazil, United States of America
Product Candidate
TAF/FTC (Descovy), TDF/FTC (Truvada)
Sponsors
Gilead, HPTN
Trial Name

Purpose 4/ HPTN 103

Planned
Prevention Option
PrEP
Start Date
End Date
Population
Injecting drug users
Product Candidate
Lenacapavir
Trial Name

PURPOSE 3/ HPTN 102

Planned
Prevention Option
PrEP
Start Date
End Date
Population
Cisgender Women
Product Candidate
Lenacapavir, TDF/FTC (Truvada)
Trial Name

HPTN 074

Completed
Prevention Option
PrEP, Treatment U=U
Start Date
February 1, 2015
End Date
June 30, 2018
Population
Injecting drug users, People Living with HIV
Country
Indonesia, Thailand, Ukraine
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
HPTN, NIAID, NIDA
Trial Name

HPTN 094/ INTEGRA

Ongoing
Prevention Option
PrEP, Treatment U=U
Start Date
June 9, 2021
End Date
Population
Cisgender Men, Cisgender Women, Injecting drug users, People Living with HIV
Country
United States of America
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
NIAID (DAIDS ID: 38715)
Trial Name

HVTN 141/ HPTN 105

Prevention Option
PrEP
Start Date
March 1, 2023
End Date
March 1, 2024
Population
Cisgender Men, Cisgender Women
Trial Name

IPM 056 / CCN019B

Ongoing
Prevention Option
MPTs, PrEP
Start Date
June 1, 2022
End Date
September 23, 2023
Population
Cisgender Women
Country
United States of America
Product Candidate
Dapivirine-Levonorgestrel ring
Sponsors
IPM, NICHD, NIH
Trial Name

HPTN 096

Ongoing
Prevention Option
PrEP, Treatment U=U
Start Date
April 1, 2022
End Date
June 30, 2027
Population
Gay and Bisexual Men Who Have Sex with Men, People Living with HIV
Product Candidate
JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI
Sponsors
DIAID, HPTN, NAID
Trial Name

Cabotegravir implant (Preclinical)

Completed
Prevention Option
Microbicides, PrEP
Start Date
End Date
Population
Cisgender Men
Country
United States of America
Product Candidate
Cabotegravir (GSK 744)
Sponsors
NIAID
Trial Name

EBONI

Ongoing
Prevention Option
PrEP
Start Date
August 23, 2022
End Date
August 19, 2024
Population
Cisgender Women, Transgender Women
Product Candidate
Cabotegravir (GSK 744)
Sponsors
ViiV
Trial Name

CONRAD 137

Completed
Prevention Option
PrEP
Start Date
October 6, 2016
End Date
October 5, 2017
Population
Cisgender Women
Product Candidate
F/TAF, TDF/FTC (Truvada)
Trial Name

CAPRISA 018

Ongoing
Prevention Option
PrEP
Start Date
January 1, 2017
End Date
December 31, 2022
Population
Cisgender Women
Product Candidate
tenofovir
Sponsors
Centre for the AIDS Programme of Research in South Africa, Saint-Etienne, Stichting Amsterdam Institute for Global Health and Development, Université Jean Monnet
Trial Name

PURPOSE 2

Ongoing
Prevention Option
PrEP
Start Date
June 14, 2021
End Date
April 1, 2027
Population
Cisgender Men, Gay and Bisexual Men Who Have Sex with Men, Transgender Men, Transgender Women
Country
United States of America
Product Candidate
Lenacapavir, JS7 DNA Vaccine, EDC ConM SOSIP, BG505 MD39.3 gp151 mRNA, MVA.tHIVcnsv4, ChAdOx1.HTI, F/TDF
Sponsors
Gilead
Trial Name

CONRAD A15-140

Completed
Prevention Option
Microbicides, PrEP
Start Date
April 7, 2016
End Date
August 5, 2016
Population
Cisgender Women
Country
United States of America
Product Candidate
TFV ring, TDF/FTC (Truvada)
Trial Name

Impower 022

Stopped Early
Prevention Option
PrEP
Start Date
February 24, 2021
End Date
July 5, 2024
Population
Cisgender Women
Country
South Africa, United States of America
Product Candidate
Islatravir (MK-8591), TDF/FTC (Truvada)
Sponsors
Merck Sharp & Dohme Corp.
Trial Name

MTN-041/ MAMMA

Ongoing
Prevention Option
Microbicides, PrEP
Start Date
May 31, 2018
End Date
November 2, 2018
Population
Cisgender Women
Country
Malawi, South Africa, Uganda, Zimbabwe
Product Candidate
TDF/FTC (Truvada), Dapivirine Ring
Sponsors
NIAID (DAIDS-ES: 38161)
Trial Name

Impower 024

Stopped Early
Prevention Option
PrEP
Start Date
March 15, 2021
End Date
September 27, 2024
Population
Cisgender Men, Gay and Bisexual Men Who Have Sex with Men, Transgender Women
Product Candidate
Islatravir (MK-8591)
Sponsors
Merck Sharp & Dohme Corp.
Trial Name

MTN-003C (VOICE Community Substudy)

Completed
Prevention Option
Microbicides, PrEP
Start Date
June 15, 2010
End Date
July 18, 2012
Population
Cisgender Women
Country
South Africa
Sponsors
DAIDS, NIAID, NIH
Trial Name

SSPN formulations of novel emtricitabine

Prevention Option
PrEP
Start Date
End Date
Population
Product Candidate
emtricitabine
Trial Name

Transdermal Delivery System for Tenofovir Alafenamide

Stopped Early
Prevention Option
PrEP
Start Date
End Date
Population
Product Candidate
F/TAF
Sponsors
CONRAD, Corporation of Mercer University, Eastern Virginia Medical School, USAID/PEPFAR

showing 1-20 of 134